Patents by Inventor Mingxing Zhou
Mingxing Zhou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9295645Abstract: This disclosure relates to a buprenorphine sustained release delivery system for treatment of conditions ameliorated by buprenorphine compounds. The sustained release delivery system includes a flowable composition containing a suspension of buprenorphine, a metabolite, or a prodrug thereof.Type: GrantFiled: June 6, 2011Date of Patent: March 29, 2016Assignee: Indivior UK LimitedInventors: Richard L. Norton, Mingxing Zhou
-
Patent number: 9272044Abstract: The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to about 3 months. The buprenorphine sustained release delivery system includes a flowable composition and a solid implant for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The implant is produced from the flowable composition. The buprenorphine sustained release delivery system provides in situ 1-month and 3-month release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis.Type: GrantFiled: January 30, 2015Date of Patent: March 1, 2016Assignee: Indivior UK LimitedInventors: Richard L. Norton, Andrew Watkins, Mingxing Zhou
-
Publication number: 20150216988Abstract: The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to about 3 months. The buprenorphine sustained release delivery system includes a flowable composition and a solid implant for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The implant is produced from the flowable composition. The buprenorphine sustained release delivery system provides in situ 1-month and 3-month release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis.Type: ApplicationFiled: January 30, 2015Publication date: August 6, 2015Inventors: Richard L. Norton, Andrew Watkins, Mingxing Zhou
-
Patent number: 8975270Abstract: The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to about 3 months. The buprenorphine sustained release delivery system includes a flowable composition and a solid implant for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The implant is produced from the flowable composition. The buprenorphine sustained release delivery system provides in situ 1-month and 3-month release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis.Type: GrantFiled: March 15, 2013Date of Patent: March 10, 2015Assignee: RB Pharmaceuticals LimitedInventors: Richard L. Norton, Andrew Watkins, Mingxing Zhou
-
Patent number: 8921387Abstract: The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to about 3 months. The buprenorphine sustained release delivery system includes a flowable composition and a solid implant for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The implant is produced from the flowable composition. The buprenorphine sustained release delivery system provides in situ 1-month and 3-month release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis.Type: GrantFiled: June 6, 2011Date of Patent: December 30, 2014Assignee: RB Pharmaceuticals LimitedInventors: Richard L. Norton, Andrew Watkins, Mingxing Zhou
-
Publication number: 20130210853Abstract: The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to about 3 months. The buprenorphine sustained release delivery system includes a flowable composition and a solid implant for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The implant is produced from the flowable composition. The buprenorphine sustained release delivery system provides in situ 1-month and 3-month release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis.Type: ApplicationFiled: June 6, 2011Publication date: August 15, 2013Applicant: RB PHARMACEUTICALS LIMITEDInventors: Richard L. Norton, Andrew Watkins, Mingxing Zhou
-
Publication number: 20130202658Abstract: This disclosure relates to a buprenorphine sustained release delivery system for treatment of conditions ameliorated by buprenorphine compounds. The sustained release delivery system includes a flowable composition containing a suspension of buprenorphine, a metabolite, or a prodrug thereof.Type: ApplicationFiled: June 6, 2011Publication date: August 8, 2013Applicant: RB PHARMACEUTICALS LIMITEDInventors: Richard L. Norton, Mingxing Zhou
-
Patent number: 8215607Abstract: A damping device for a stay cable including a rotating lever, a lever support saddle, a longitudinal connecting member, and a rigid connection rod. When the stay cable vibrates inside or outside the plane thereof, the vibration displacement is transferred to the rotating lever through the rigid connection rod. One end of the rotating lever is connected to the lever support saddle via the longitudinal connecting member, and can rotate up and down with the lever support saddle as the axis and rotate around its central axis. The other end of the rotating lever is connected to a mass block and a damper. The damping device effectively inhibits vibrations inside and outside the stay cable plane, is easy to install and maintain, and does not negatively impact the appearance of a cable-stayed bridge.Type: GrantFiled: July 8, 2011Date of Patent: July 10, 2012Assignees: Bridge Science Research Institute Ltd., China Zhongtie Major Bridge Engineering Group, China Railway Major Bridge Engineering Co., Ltd.Inventors: Zhengxing Wang, Cuicui Guo, Mingxing Zhou, Zhiyang Tong, Guiqiong Hu, Baohui Cheng, Jiwei Zhong, Bo Wang, Jian Zhao, Wu Li
-
Patent number: 8173148Abstract: The invention relates to a delivery system for the sustained and controlled delivery of a group of bioactive agents. More particularly, the invention relates to a delivery system and a method for delivery of a bioactive agent containing a nucleophilic functional group by means of a biodegradable, sustained-release implant. The implant may be a preformed implant, microparticles or an in situ formed implant. The implant includes a biodegradable thermoplastic polymer, the bioactive agent having a nucleophilic group substituent and a stabilizing associate as well as other optional components. The combination of the stabilizing associate with the bioactive agent prevents and/or minimizes and/or lessens degradation of the thermoplastic polymer by the bioactive agent.Type: GrantFiled: November 10, 2005Date of Patent: May 8, 2012Assignee: Tolmar Therapeutics, Inc.Inventors: Eric Dadey, Mingxing Zhou
-
Publication number: 20120006965Abstract: A damping device for a stay cable including a rotating lever, a lever support saddle, a longitudinal connecting member, and a rigid connection rod. When the stay cable vibrates inside or outside the plane thereof, the vibration displacement is transferred to the rotating lever through the rigid connection rod. One end of the rotating lever is connected to the lever support saddle via the longitudinal connecting member, and can rotate up and down with the lever support saddle as the axis and rotate around its central axis. The other end of the rotating lever is connected to a mass block and a damper. The damping device effectively inhibits vibrations inside and outside the stay cable plane, is easy to install and maintain, and does not negatively impact the appearance of a cable-stayed bridge.Type: ApplicationFiled: July 8, 2011Publication date: January 12, 2012Inventors: Zhengxing WANG, Cuicui GUO, Mingxing ZHOU, Zhiyang TONG, Guiqiong HU, Baohui CHENG, Jiwei ZHONG, Bo WANG, Jian ZHAO, Wu LI
-
Patent number: 8017144Abstract: The present invention is directed to an improved system for controlled release of a bone growth promoting compound and to a flowable composition for its formation. The flowable composition is composed of a bone growth promoting compound, a thermoplastic polymer and an organic solvent. The flowable composition is capable of forming a biodegradable and/or bioerodible microporous, solid polymer matrix. The matrix is useful as an implant in patients (humans and animals) for delivery of a bone growth promoting compound to certain tissues.Type: GrantFiled: October 24, 2008Date of Patent: September 13, 2011Assignee: Pfizer Inc.Inventors: Francis Dumont, Richard L. Dunn, Scott A. Jeffers, Richard W. Korsmeyer, Mei Li, Vishwas M. Paralkar, Mingxing Zhou
-
Publication number: 20090169595Abstract: The present invention is directed to an improved system for controlled release of a bone growth promoting compound and to a flowable composition for its formation. The flowable composition is composed of a bone growth promoting compound, a thermoplastic polymer and an organic solvent. The flowable composition is capable of forming a biodegradable and/or bioerodible microporous, solid polymer matrix. The matrix is useful as an implant in patients (humans and animals) for delivery of a bone growth promoting compound to certain tissues.Type: ApplicationFiled: October 24, 2008Publication date: July 2, 2009Inventors: Francis Dumont, Richard L. Dunn, Scott A. Jeffers, Richard W. Korsmeyer, Mei Li, Vishwas M. Paralkar, Mingxing Zhou
-
Publication number: 20080299168Abstract: The invention relates to a delivery system for the sustained and controlled delivery of a group of bioactive agents. More particularly, the invention relates to a delivery system and a method for delivery of a bioactive agent containing a nucleophilic functional group by means of a biodegradable, sustained-release implant. The implant may be a preformed implant, microparticles or an in situ formed implant. The implant includes a biodegradable thermoplastic polymer, the bioactive agent having a nucleophilic group substituent and a stabilizing associate as well as other optional components. The combination of the stabilizing associate with the bioactive agent prevents and/or minimizes and/or lessens degradation of the thermoplastic polymer by the bioactive agent.Type: ApplicationFiled: November 10, 2005Publication date: December 4, 2008Inventors: Eric Dadey, Mingxing Zhou
-
Publication number: 20060121085Abstract: The present invention provides a flowable composition suitable for use as a controlled release implant. The composition includes: (a) a biodegradable, biocompatible thermoplastic polymer that is at least substantially insoluble in aqueous medium, water or body fluid; (b) a cell-cycle dependent biological agent, a schedule-dependent biological agent, a metabolite thereof, a pharmaceutically acceptable salt thereof, or a prodrug thereof; and (c) a biocompatible organic liquid, at standard temperature and pressure, in which the thermoplastic polymer is soluble. The present invention also provides a method of treating cancer in a mammal. The present invention also provides a method of blocking, impeding, or otherwise interfering with cell cycle progression at the G1-phase, G1/S interphase, S-phase, G2/M interface or M-phase of the cell cycle in a mammal. The methods includes administering to a mammal an effective amount of a flowable composition of the present invention.Type: ApplicationFiled: September 9, 2005Publication date: June 8, 2006Inventors: Stephen Warren, Eric Dadey, Mingxing Zhou, Richard Dunn
-
Patent number: 6630155Abstract: The invention provides a controlled release polymeric composition which includes a base polymer or copolymer, an organic solvent, a polymeric controlled release additive, and a biologically active agent. The polymeric controlled release additive reduces the initial burst of biologically active agent released from the polymeric composition as it is solidifying to form the solid implant. The controlled release additive is preferably a poly(lactide-co-glycolide)/polyethylene glycol block copolymer.Type: GrantFiled: August 22, 2000Date of Patent: October 7, 2003Assignee: Atrix Laboratories, Inc.Inventors: Bhagya L. Chandrashekar, Mingxing Zhou, Eileen M. Jarr, Richard L. Dunn
-
Publication number: 20030104031Abstract: The present invention is directed to an improved system for controlled release of a bone growth promoting compound and to a flowable composition for its formation. The flowable composition is composed of a bone growth promoting compound, a thermoplastic polymer and an organic solvent. The flowable composition is capable of forming a biodegradable and/or bioerodible microporous, solid polymer matrix. The matrix is useful as an implant in patients (humans and animals) for delivery of a bone growth promoting compound to certain tissues.Type: ApplicationFiled: November 25, 2002Publication date: June 5, 2003Inventors: Francis Dumont, Richard L. Dunn, Scott A. Jeffers, Richard W. Korsmeyer, Mei Li, Vishwas M. Paralkar, Mingxing Zhou
-
Patent number: 6143314Abstract: The invention provides a controlled release polymeric composition which includes a base polymer or copolymer, an organic solvent, a polymeric controlled release additive, and a biologically active agent. The polymeric controlled release additive reduces the initial burst of biologically active agent released from the polymeric composition as it is solidifying to form the solid implant. The controlled release additive is preferably a poly(lactide-co-glycolide)/polyethylene glycol block copolymer.Type: GrantFiled: October 28, 1998Date of Patent: November 7, 2000Assignee: Atrix Laboratories, Inc.Inventors: Bhagya L. Chandrashekar, Mingxing Zhou, Eileen M. Jarr, Richard L. Dunn